Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisPatricia Cortazar, Gϋnter von Minckwitz, Sibylle Loibl et al.|The Lancet|2014Cited by 4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell LymphomaBhupinder Mann, Richard Pazdur, John R. Johnson et al.|The Oncologist|2007Cited by 1.4k
Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell CarcinomaVicki Goodman, Richard Pazdur, Edwin P. Rock et al.|Clinical Cancer Research|2007Cited by 495
Sorafenib for the Treatment of Advanced Renal Cell CarcinomaRobert C. Kane, Richard Pazdur, Ann T. Farrell et al.|Clinical Cancer Research|2006Cited by 466
Approval Summary: Imatinib Mesylate in the Treatment of Metastatic and/or Unresectable Malignant Gastrointestinal Stromal TumorsMartin H. Cohen, Richard Pazdur, Ann T. Farrell et al.|The Oncologist|2009Cited by 429